Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, et al
It also shows that doubling up the next dose to "catch up" creates a dangerous spike that exceeds anything in your normal protocol
IGF-1 is one of the best-studied positive regulators of this cycle, promoting satellite-cell proliferation and differentiation and driving protein synthesis in mature fibers through the Akt/mTOR pathway
The one problem is that the stock is expensive, with a price-to-earnings ratio of 35x, as earnings appear to be catching up to the stock's lofty price
Most clinical trials employed gradual dose titration protocols specifically to minimize gastrointestinal side effects, with discontinuation rates due to GI adverse events ranging from 47% in the STEP trials